Skip to main content

Bispecific Antibody Deal Benchmarks in Hematology

Median Upfront
$871M
Range: $454M - $1.3B
Total Deal Value
$4.3B
Range: $2.7B - $6.0B
Royalty Rate
9.6% - 17.9%
Tiered up to 21.9%
Dev Milestones
$730M
Range: $471M - $991M
Model Your Deal

Market Analysis

Bispecific Antibody therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 bispecific antibody asset in hematology is $871M, with total deal values reaching $4.3B. Development milestones average $730M, while regulatory milestones contribute $870M.

The hematology bispecific antibody landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for bispecific antibody hematology deals range from 9.6% to 17.9% at the base tier, with tiered escalation reaching 13.6%-21.9% on blockbuster sales. Commercial milestones averaging $1.9B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a bispecific antibody hematology licensing deal?
Based on our analysis, Phase 2 bispecific antibody licensing deals in hematology average $871M in upfront payments, with a range of $454M to $1.3B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for bispecific antibody hematology transactions?
The median total deal value for Phase 2 bispecific antibody assets in hematology is $4.3B, ranging from $2.7B to $6.0B. This includes development milestones ($730M), regulatory milestones ($870M), and commercial milestones ($1.9B).
What royalty rates are standard for bispecific antibody deals in hematology?
Base royalty rates for bispecific antibody hematology transactions range from 9.6% to 17.9%, with tiered escalations reaching 13.6%-21.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in bispecific antibody hematology deals?
Bispecific Antibody hematology deals allocate approximately 80% of total deal value to milestones. Development milestones ($730M) make up the largest share, followed by commercial milestones ($1.9B) and regulatory milestones ($870M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

CAR-T (Hematologic) in Hematology

View

Trispecific Antibody in Hematology

View

Bispecific Antibody in Oncology

View

Bispecific Antibody in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included